Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma. - Wikidata - awgldk - TriplyDB

Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma.

Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma.

http://www.wikidata.org/entity/Q43662977

about

Hard-Wired Bias: How Even Double-Blind, Randomized Controlled Trials Can Be Skewed From the Start Novel agents in the treatment of multiple myeloma: a review about the future Monoclonal antibodies targeting CD38 in hematological malignancies and beyond Novel strategies to target the ubiquitin proteasome system in multiple myeloma Smoldering multiple myeloma Smoldering multiple myeloma requiring treatment: time for a new definition?Multiple myeloma: 2014 Update on diagnosis, risk-stratification, and management European perspective on multiple myeloma treatment strategies in 2014 Recent advances in understanding multiple myeloma Recent advances in multiple myeloma: a Korean perspective Combination therapeutics in complex diseases Smoldering multiple myeloma.Multiple myeloma epidemiology and survival: A unique malignancy.Elotuzumab: a novel immune-stimulating therapy to treat multiple myeloma.Development and Validation of an Algorithm to Identify Patients with Multiple Myeloma Using Administrative Claims Data.Transcriptome analysis reveals molecular profiles associated with evolving steps of monoclonal gammopathies.Gene expression profile alone is inadequate in predicting complete response in multiple myeloma.Diagnosis, risk stratification and management of monoclonal gammopathy of undetermined significance and smoldering multiple myeloma.Diagnosis and management of smoldering multiple myeloma: the razor's edge between clonality and cancer.How I treat smoldering multiple myeloma.Dilemmas in treating smoldering multiple myeloma.Incidence and risk factors for suicide and attempted suicide following a diagnosis of hematological malignancy.Early versus deferred treatment for smoldering multiple myeloma: a meta-analysis of randomized, controlled trials Severe reversible pulmonary hypertension in smoldering multiple myeloma: two cases and review of the literature.Profile of elotuzumab and its potential in the treatment of multiple myeloma Paradoxical resistance of multiple myeloma to proteasome inhibitors by decreased levels of 19S proteasomal subunits.Positron emission tomography-computed tomography in the diagnostic evaluation of smoldering multiple myeloma: identification of patients needing therapy.A single-arm, open-label, phase 2 clinical trial evaluating disease response following treatment with BI-505, a human anti-intercellular adhesion molecule-1 monoclonal antibody, in patients with smoldering multiple myeloma Myeloma today: Disease definitions and treatment advances.Whole body diffusion weighted MRI--a new view of myeloma.The Changing Landscape of Smoldering Multiple Myeloma: A European Perspective.Four genes predict high risk of progression from smoldering to symptomatic multiple myeloma (SWOG S0120).Doubly blind: a systematic review of gender in randomised controlled trials.Multiple Myeloma, Version 2.2016: Clinical Practice Guidelines in Oncology The Diagnosis and Treatment of Multiple Myeloma Evolving changes in disease biomarkers and risk of early progression in smoldering multiple myeloma Clinical, genomic, and imaging predictors of myeloma progression from asymptomatic monoclonal gammopathies (SWOG S0120).European Myeloma Network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myeloma.Quantification of circulating clonal plasma cells via multiparametric flow cytometry identifies patients with smoldering multiple myeloma at high risk of progression.Multiple myeloma: 2016 update on diagnosis, risk-stratification, and management.

P2860

Q24289425-DD50F8BE-7A86-44DF-BBE8-BBBB857D0481 Q26745924-B0402AA4-CBF4-466B-B45B-13CDD732D4FA Q26766718-29CED6D1-14EC-4763-AD6D-9308EF8AAB65 Q26773246-429A2419-C153-468E-BDDB-A9DA06933E39 Q26863331-067ED2AD-AF08-4BB9-928A-D9F03AE274B2 Q26996579-522702E8-C44E-43DD-AE10-37D1C6FC8159 Q26998884-37502A39-922D-4544-A4AA-CB7C165B37EF Q27005966-5AE9DD15-2669-4F16-AF3C-9C8E01D6DCB0 Q28070331-0F5C543B-E5F0-416F-82F6-C6ABB2E02244 Q28074521-E1D7760D-EA73-4A88-A169-2FAB20515A56 Q28076891-F385D58B-CC7F-48C6-8F51-29EFF4A7B8A8 Q28082855-51186DA2-1832-4528-877D-23160EC79813 Q30239771-EB414316-8A49-4DF7-BD7C-15395240D4E2 Q30249513-36ACDF86-273E-48E8-97FE-381A15106096 Q31141905-2CD217C8-B5C6-42E8-AFBD-6CD3D33947AB Q33978937-2B179F8C-D81A-4343-A916-D6364E0F9B52 Q34345502-69491BCE-8F6E-40BA-90CA-6F227A11B0FE Q34525834-1DE5BA2A-147A-452D-B295-810621331B2A Q34557651-D136CE2C-6A5C-494F-AC98-6C09D5C8893D Q34580094-4711DB04-F39C-497A-81ED-F4C5FED2353D Q34716500-8487F5F7-6836-4833-9522-BF41D3B34B7D Q35032345-745728E9-73CE-4875-963B-E4575EB97EAE Q35298727-71D0E8A1-84B8-427F-80BF-895A2B8D123C Q35517369-0348657E-D3E9-4143-A3F7-E8845A659547 Q35628678-410C277A-68DB-4A29-85F5-F6C5094B7A6F Q36150369-7E30884D-FFB2-4BEC-9109-7CFA69B2EAC2 Q36254248-9C677C16-80CE-4BE4-9862-2CFAC7155772 Q36270127-19438FA4-A4EF-4022-83CA-98F84CFDD1F6 Q36470699-4DE584A4-D109-4787-A036-5DD787A87B6D Q36532924-A49089A6-C083-42E5-A016-19D6019B7894 Q36673465-B237B430-1574-41DD-848B-128F62E4C262 Q36708969-A8990054-3E29-42AD-B262-5E7D4A348D90 Q36805845-4A00C2B0-C246-4169-8EE1-6623D10538D1 Q36963203-B178C937-D0DA-4B11-87C8-8BE1335893DE Q37150733-0573A9D4-7975-4F35-AD3A-0B071ADF5598 Q37271023-A1A2406B-BF0C-42CB-A194-F6292D461386 Q37429722-CDC2C762-6909-48C1-BD6F-200FD7C1DE82 Q37552008-5DE59893-98CF-42BD-BDD4-7C3A612F1D18 Q37593481-7B16772F-CAEE-4000-8467-5D6ECA647B97 Q37623809-E6A94263-0472-441A-9CE2-E67F2DB2A516

P2860

Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma.

http://www.wikidata.org/entity/Q43662977

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年学术文章

@wuu

2013年学术文章

@zh

2013年学术文章

@zh-cn

2013年学术文章

@zh-hans

2013年学术文章

@zh-my

2013年学术文章

@zh-sg

2013年學術文章

@yue

2013年學術文章

@zh-hant

name

Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma.

@en

Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma.

@nl

type

label

Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma.

@en

Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma.

@nl

prefLabel

Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma.

@en

Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma.

@nl

P1433

Q43662977-BAE5688F-C1F9-40A8-9F61-0A96E71483B6

P1476

Q43662977-68F071BB-355C-4C00-BBD2-605069E766A5

P2093

Q43662977-0DA1A7A6-2523-4901-B36A-EE3D2A954FF9

Q43662977-1456B503-28C7-4607-B1E3-836A413E3408

Q43662977-149A8018-9A3D-4BF9-9E8F-89DD3A11CA34

Q43662977-3B248B9C-1252-4BE5-A844-63066385A88C

Q43662977-4C6DF867-E136-4C88-A177-B6E99618ED25

Q43662977-4DC37D95-C2D6-4B66-A1A8-9E67744B4710

Q43662977-519E589E-F49E-4D59-8D71-7E5D9F31AAFE

Q43662977-67A53297-3C61-4897-9DD5-79276E6C05A5

Q43662977-91ED379E-DED8-4104-88F7-BCF41B4DD8C1

Q43662977-A0C10C82-E0EF-42CF-B01B-BE0F8221C9A5

P304

Q43662977-E6E2EFC6-2502-4A59-89DD-3C05DDFAAF23

P31

Q43662977-6286F687-E4B2-4826-9CE9-509FAE8816BF

P356

Q43662977-AFFFA182-C649-4743-A029-72E08525EA99

P407

Q43662977-36F53C4C-9148-4FD9-81A8-3FB502976BB2

P433

Q43662977-0300FD95-D80D-48C2-A6A3-9C135902C8B0

P478

Q43662977-49714F2B-DBA6-48AC-9FC5-DA35C1307869

P50

Q43662977-1093C11B-1E88-421D-858F-061A38812647

Q43662977-89B98FE9-8DC5-4E7B-959F-D887909116C0

P577

Q43662977-F48B424B-FD95-424D-84FF-8E250D166D9B

P698

Q43662977-892300A1-620B-4565-A5C8-63BB4D24CB0E

P921

Q43662977-1B2C18C0-B272-42FE-A4F5-EA1C2917B0FB

P356

P1433

The New England Journal of Medicine

P1476

Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma.

@en

P2093

Albert Oriol

http://www.w3.org/2001/XMLSchema#string

Bruno Paiva

http://www.w3.org/2001/XMLSchema#string

Eduardo Olavarría

http://www.w3.org/2001/XMLSchema#string

Felipe de Arriba

http://www.w3.org/2001/XMLSchema#string

Javier López

http://www.w3.org/2001/XMLSchema#string

Jesús-F San Miguel

http://www.w3.org/2001/XMLSchema#string

Joan Bargay

http://www.w3.org/2001/XMLSchema#string

Joan Bladé

http://www.w3.org/2001/XMLSchema#string

José-Luis García

http://www.w3.org/2001/XMLSchema#string

Juan-José Lahuerta

http://www.w3.org/2001/XMLSchema#string

P304

438-447

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1056/NEJMOA1300439

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

369

http://www.w3.org/2001/XMLSchema#string

P50

Javier de la Rubia

P577

2013-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23902483

http://www.w3.org/2001/XMLSchema#string

P921